Correction: Amr et al. Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort. Reviews in Cardiovascular Medicine. 2024; 25(6): 225 Authors: Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani Published: 2026 The authors would like to correct Table 1 (Ref. [1,2]) of Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort [3], as errors were introduced in Table 1. The authors declare that these corrections do not change the result or conclusion of this paper. We sincerely apologize for having this error in the article, and apologize for any inconvenience caused. The authors have provided a corrected version of Table 1 (Ref. [4,5])here: The original Table 1: Table 1. Inclusion and exclusion criteria of EXPLORER-HCM and SEQUOIA-HCM clinical trials [1,2].EXPLORER-HCM clinical trial investigating MavacamtenKey inclusion criteriaKey exclusion criteriaAged at least 18 yearsHistory of syncope or sustained ventricular tachyarrhythmia with exercise within the past 6 monthsDiagnosed with obstructive HCM (LV hypertrophy with max LV wall thickness ≥15 mm or ≥13 mm if familial HCM)QT interval corrected >500 ms using Fridericia’s formulaPeak LVOT gradient at least 50 mmHg (at rest, after Valsalva manoeuvre or exercise)Paroxysmal or intermittent atrial fibrillation present on screening ECGLeft ventricular ejection fraction (LVEF) at least 55%Persistent or permanent atrial fibrillation not on anticoagulation for 4 weeks+ or not adequately rate-controlled within the past 6 monthsNYHA class II–III symptoms and able to perform upright CPETPatients on stable doses of β blockers or calcium channel blockers for at least 2 weeks before screening, without anticipated changes during the study (except disopyramide)SEQUOIA-HCM clinical trial investigating AficamtenKey inclusion criteriaKey exclusion criteriaAdults between 18 and 85 years of age at screeningAortic stenosis or fixed subaortic obstruction or moderate-severe mitral regurgitation not due to systolic anterior motion of the mitral valveBody weight ≥35 kg at screeningKnown infiltrative or storage disorder causing cardiac hypertrophy that mimics HOCM (e.g., Noonan syndrome, Fabry disease, amyloidosis)Diagnosed with HOCM per the following criteria:(a) LV hypertrophy and non-dilated LV chamber in the absence of other cardiac disease.(b) Minimal wall thickness ≥15 mm (minimal wall thickness ≥13 mm is acceptable with positive family history of HCM or with known disease-causing gene mutation)History of LV systolic dysfunction (LVEF <45%) at any time during their clinical courseAdequate acoustic windows for echocardiographyInability to exercise on a treadmill or bicycleResting LVOT gradient ≥30 mmHg and <50 mmHg AND post-Valsalva LVOT-G ≥50 mmHgHas been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or plans for either treatment during the study periodLVEF ≥60% at screeningHistory of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months before screeningNYHA functional class II or III at screeningHas received prior treatment with Aficamten or MavacamtenPatients on beta-blockers, verapamil, diltiazem, or ranolazine should have been on stable doses for >6 weeks prior to randomization and anticipate remaining on the same medication regimen during the studyParoxysmal atrial fibrillation or flutter documented during the screening periodHemoglobin ≥10 g/dL at screeningParoxysmal or permanent atrial fibrillation is only excluded if: (1) rhythm restoring treatment has been required ≤6 months prior to screening or (2) rate control and anticoagulation have not been achieved for at least 6 months prior to screeningCPET, cardiopulmonary exercise stress testing; ECG, electrocardiogram; HOCM, hypertrophic obstructive cardiomyopathy; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; HCM, hypertrophic cardiomyopathy; LV, left ventricular. Inclusion and exclusion criteria of EXPLORER-HCM and SEQUOIA-HCM clinical trials [1,2]. CPET, cardiopulmonary exercise stress testing; ECG, electrocardiogram; HOCM, hypertrophic obstructive cardiomyopathy; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; HCM, hypertrophic cardiomyopathy; LV, left ventricular. The corrected Table 1: Table 1. Inclusion and exclusion criteria of EXPLORER-HCM and SEQUOIA-HCM clinical trials [4,5].EXPLORER-HCM clinical trial investigating MavacamtenKey inclusion criteriaKey exclusion criteriaAged at least 18 yearsHistory of syncope or sustained ventricular tachyarrhythmia with exercise within the past 6 monthsDiagnosed with obstructive HCM (LV hypertrophy with max LV wall thickness ≥15 mm or ≥13 mm if familial HCM)QT interval corrected >500 ms using Fridericia’s formulaPeak LVOT gradient at least 50 mmHg (at rest, after Valsalva manoeuvre or exercise)Paroxysmal or intermittent atrial fibrillation present on screening ECGLeft ventricular ejection fraction (LVEF) at least 55%Persistent or permanent atrial fibrillation not on anticoagulation for 4 weeks+ or not adequately rate-controlled within the past 6 monthsNYHA class II–III symptoms and able to perform upright CPETPatients were allowed to continue standard hypertrophic cardiomyopathy medical therapy except disopyramide, including monotherapy with β blockers or calcium channel blockers, if dosing remained stable for at least 2 weeks before screening and no changes were anticipated during the study.SEQUOIA-HCM clinical trial investigating AficamtenKey inclusion criteriaKey exclusion criteriaAdults between 18 and 85 years of age at screeningModerate-severe valvular aortic stenosis and/or regurgitation. Moderate-severe mitral regurgitation not caused by systolic anterior motion of the mitral valveBMI <35 kg/m2 Known or suspected infiltrative, genetic, or storage disorder causing cardiac hypertrophy that mimics HOCM (e.g., Noonan syndrome, Fabry disease, amyloidosis)Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory of• ≥15 mm in ≥1 myocardial segment OR• ≥13 mm in ≥1 wall segment and a known-disease-causing gene mutation or positive family history of HCMHistory of LV systolic dysfunction (LVEF <45%) or stress cardiomyopathy at any time during the clinical course of the diseaseRER ≥1.05 and pVO2 ≤90% predicted on the screening CPET per the core laboratoryInability to exercise on a treadmill or bicycle (e.g., orthopedic limitations)Resting LVOT gradient ≥30 mmHg AND post-Valsalva LVOT-G ≥50 mmHgHas been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or plans for either treatment during the study periodLVEF ≥60% at screeningHistory of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months before screeningNYHA functional class II or III at screening.Has received prior treatment with aficamten or mavacamtenPatients on beta-blockers, verapamil, diltiazem, or disopyramide should have been on stable doses for >6 weeks prior to randomization and anticipate remaining on the same medication regimen during the study. Patients treated with disopyramide must also be concomitantly treated with a beta-blocker and/or calcium-channel blockerParoxysmal atrial fibrillation documented during the screening periodHemoglobin ≥10 g/dL at screeningParoxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (e.g., direct-current cardioversion, atrial fibrillation ablation procedure, or antiarrhythmic therapy) ≤6 mo before screening (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for >6 mo).CPET, cardiopulmonary exercise stress testing; ECG, electrocardiogram; HOCM, hypertrophic obstructive cardiomyopathy; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; HCM, hypertrophic cardiomyopathy; LV, left ventricular. Inclusion and exclusion criteria of EXPLORER-HCM and SEQUOIA-HCM clinical trials [4,5]. CPET, cardiopulmonary exercise stress testing; ECG, electrocardiogram; HOCM, hypertrophic obstructive cardiomyopathy; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; HCM, hypertrophic cardiomyopathy; LV, left ventricular. This has been corrected as of June 4, 2026. The authors apologize for these errors.